Efficacy of Nimotuzumab Combined with Docetaxel–Cisplatin–Fluorouracil Regimen in Treatment of Advanced Oral Carcinoma

Meng, Jian; Gu, Qianping; Meng, Qingfei; Zhang, Jie; Li, Zhiping; Si, Yameng; Guo, Wei; Zhuang, Qiya

doi:10.1007/s12013-013-9686-5

Cited by 6 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, it was found that adjuvant radiotherapy did not improve the 5-year survival rate of patients with early tongue cancer. Our finding was opposite to reports in literature (15,16), and the possible reason could be that the recruited patients with early tongue cancer had relatively milder symptoms. Surgery caused great tissue injury to the patient's body.…”

Section: Discussioncontrasting

confidence: 99%

Surgical treatment of early tongue squamous cell carcinoma and patient survival

Zhu¹,

Wang²,

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Surgical options for treating early tongue squamous cell carcinoma and patient survival were explored. Clinical records of 128 patients with early tongue squamous cell carcinoma who were treated in Henan Province Hospital of TCM from June, 2010 to June, 2013 were retrospectively analyzed. According to adopted treatment plan, the patients were divided into 3 groups: 42 patients in surgical therapy alone group, 46 patients in preoperative radiotherapy group, and 40 patients in postoperative radiotherapy group. Statistical analysis was performed on the general data of patients and clinical records, as well as the 5-year survival rate and recurrence rate. The overall 5-year survival rate for all patients was 86.7% (111/128), and the 5-year disease-specific survival rate was 88.8% (111/125). In the individual groups, the 5-year survival rate and the 5-year disease-specific survival rate were 91.3% (84/92) and 91.3% (84/92), respectively, in the surgical therapy alone group 76.9% (10/13) and 83.3% (10/12), respectively, in the preoperative radiotherapy group, and 73.9% (17/23) and 81.0% (17/21), respectively, in the postoperative radiotherapy group. There were no statistically significant differences in 5-year survival rate (χ 2 =5.990, P=0.051) and 5-year disease-specific survival rate (χ 2 =2.223, P=0.329) among the three groups. In total, there were 25 cases of recurrence during follow-up. The recurrence rate was 19.5%; the local recurrence rate was 11.7% (15/128); and the regional recurrence rate was 7.8% (10/128). There were 6 cases of metastasis, and the metastatic rate was 4.7%. There were no statistically significant differences in recurrence rate and metastatic rate among the three groups. Compared with surgical therapy alone, radiotherapy combined with surgical therapy neither improved 5-year survival rate nor reduced recurrence rate. Therefore, surgical therapy alone is suggested to be the preferred option for treating early tongue squamous cell carcinoma.

show abstract

Section: Discussioncontrasting

confidence: 99%

Surgical treatment of early tongue squamous cell carcinoma and patient survival

Zhu¹,

Wang²,

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Two studies 31 , 47 evaluated the use of CT, one of them was a controlled clinical trial, 47 and another was an observational retrospective study. 31 One study 47 included 21 participants in the intervention group, whereas the other study 31 included just 8 people in the intervention group. All two studies 31 , 47 focused on patients with clinical stage III/IV oral cancer.…”

Section: Resultsmentioning

confidence: 99%

“… 31 One study 47 included 21 participants in the intervention group, whereas the other study 31 included just 8 people in the intervention group. All two studies 31 , 47 focused on patients with clinical stage III/IV oral cancer.…”

Section: Resultsmentioning

confidence: 99%

“…At a median follow-up of 69 months, the 1-year, 3-year, and 5-year OS rates were 80%, 71%, and 64%, respectively. Similarly, Meng 31 evaluated the use of the docetaxel-cisplatin-FU regimen, showing a response rate of 37.5% and a disease control rate of 62.5%. However, few studies are assessing the use of CT alone for unresectable oral cancer, so its effectiveness should be determined.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Anaya¹,

Amador²,

Acosta³

2021

CMAR

View full text Add to dashboard Cite

Purpose This review describes the current scientific evidence of therapeutic options in unresectable oral squamous cell carcinoma. Methods This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched MEDLINE (Via PubMed) to identify studies assessing treatments for unresectable oral squamous cell carcinoma. The methodological quality assessment of the included studies was performed using the Joanna Briggs Institute (JBI) checklist tool. The evidence was organized and presented using tables and narrative synthesis. Results Thirty-three studies met the eligibility criteria. Most studies had an observational design. The sample size varied from 16 to 916 participants. The methodology quality of the included studies ranged from 2.5 to 10 using the JBI tool. Overall, the optimal treatment of patients with unresectable oral cancer is challenging, so there is a sprinkling of studies assessing a variety of therapeutic options, such as radiotherapy, chemotherapy, concurrent chemoradiotherapy, immunotherapy, targeted therapy plus chemotherapy or radiotherapy, and gene therapy plus chemotherapy. Conclusion There is lacking evidence about the benefits of some therapeutic options for unresectable oral squamous cell carcinoma. Overall, these patients can be treated using a multimodal approach such as concurrent chemoradiotherapy or induction chemotherapy followed by chemoradiotherapy, which have shown good clinical outcomes. However, other options could be considered depending on the assessment of risk/benefits, tumor extension, and patient values and preferences.

show abstract

“…Cetuximab was shown in a previous study to circumvent irinotecan resistance in irinotecan-refractory colorectal cancer (23). In metastatic/recurrent head and neck squamous-cell carcinoma (HNSCC) or squamous-cell lung cancer, the addition of these molecular-targeted agents, such as cetuximab, nimotuzumab, panitumumab, necitumumab, to platinum-based chemotherapy also improves the response rate and survival (13,(24)(25)(26)(27). Chan et al found a dose-dependent additive enhanced antitumor activity when cetuximab was combined with cisplatin or taxanes in NPC cell lines (28) and then confirmed its clinical activity in combination with carboplatin in heavily pretreated patients with mNPC (14).…”

Section: Discussionmentioning

confidence: 99%

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen

Zhang

Huang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Purpose: Metastatic nasopharyngeal carcinoma (mNPC) remains incurable. This prospective study aimed to investigate whether adding cetuximab to cisplatin-based induction therapy could improve efficacy and survival for chemotherapy-naïve mNPC patients.Patients and Methods: Eligible chemotherapy-naïve mNPC patients were enrolled, including those initially diagnosed with mNPC (IM) and those with first-relapse metastases after radiotherapy (RM). Patients all received induction chemotherapy (IC) including docetaxel and cisplatin plus cetuximab. Those who obtained objective remission after IC would continue to receive radiotherapy concurrent with cetuximab and cisplatin, and further capecitabine as maintenance. Contemporaneous patients who received conventional therapy served as controls.Results: Forty-three patients were enrolled, including 17 IM and 26 RM patients. Thirty-nine (90.7%) patients had WHO III subtype. The overall response and complete response (CR) rates were, respectively, 79.1 and 34.9% after induction therapy and 76.7 and 46.5% after chemoradiotherapy. The 5-year overall survival (OS) and progression-free survival (PFS) rates reached 34.9 and 30%, respectively. Subgroup analysis showed that compared with RM patients, IM patients had a higher 5-year OS (58.8 vs. 19.2%) and PFS (52.9 vs. 19.2%). The IM group had a higher CR rate of induction treatment than the RM group (52.9 vs. 23.1%). No treatment-related death was observed. Twelve patients (27.9%) remained alive with disease-free survival times from 60+ to 135+ months. Control patients showed a substantially lower survival rate (5-year OS, 10.9%) and few long-term survivors.Zhang et al. Cetuximab-Containing Multimodality Therapy in mNPCConclusions: This regimen resulted in significantly improved efficacy and survival, which indicates a potentially curative role for chemotherapy-naïve mNPC, especially in newly diagnosed patients. A phase III clinical trial (NCT02633176) is ongoing for confirmation.

show abstract

Efficacy of Nimotuzumab Combined with Docetaxel–Cisplatin–Fluorouracil Regimen in Treatment of Advanced Oral Carcinoma

Cited by 6 publications

References 13 publications

Surgical treatment of early tongue squamous cell carcinoma and patient survival

Surgical treatment of early tongue squamous cell carcinoma and patient survival

Therapeutic Options in Unresectable Oral Squamous Cell Carcinoma: A Systematic Review

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen

Contact Info

Product

Resources

About